Oppenheimer Sees 215% Upside in Viking Therapeutics as VK2735 Options Expand Beyond Near-Term Readouts
Wall Street stays bullish on VKTX as Oppenheimer sees expanded opportunities for VK2735 beyond near-term readouts and funding into 2028.
/ 1648 items
#XY↓
Curium to Acquire Lantheus in Up to $8 Billion Radiopharma Deal
Curium will buy Lantheus for $102.50/share cash plus up to $12 CVRs, valuing the radiopharma deal at up to $8B. Closing expected in H1 2027.
Supernus and Indivior Agree to Merge, Creating $2.2 Billion CNS Biopharma Leader
Supernus and Indivior merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility.
KKR to Buy Integer Holdings for $5.7 Billion in All-Cash Deal
Shareholders get cash; company goes private by year-end.
Wells Fargo Initiates Coverage of Pyxis Oncology with $12 Target, Sees Shares Doubling on Fall Update
Dose cap de-risks MICVO as Wells Fargo starts Pyxis at Overweight with $12 target. Sees at least 2x upside on fall HNSCC update.
AstraZeneca and Bristol Myers Squibb Explore $400 Billion Pharma Merger
Cancer drugs drive sales for both, with direct overlaps like Imfinzi and Opdivo raising antitrust risks.